Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

(2014) D. C. Turner et al.   CLINICAL CANCER RESEARCH

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

(2014) Daniel J. Kingsbury et al.   CLINICAL RHEUMATOLOGY

Review on modeling anti-antibody responses to monoclonal antibodies

(2014) José David Gómez-Mantilla et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Ofatumumab for Rituximab-Resistant Nephrotic Syndrome

(2014) Biswanath Basu   NEW ENGLAND JOURNAL OF MEDICINE

Controlling Off-Label Medication Use

(2013) Muriel R. Gillick   ANNALS OF INTERNAL MEDICINE

Rituximab pharmacokinetics in children and adolescents withde novointermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report

(2013) Matthew J. Barth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

(2013) Miroslav Dostalek et al.   CLINICAL PHARMACOKINETICS

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis

(2013) Omoniyi J. Adedokun et al.   INFLAMMATORY BOWEL DISEASES

Prospective data collection of off-label use of rituximab in Australian public hospitals

(2013) K. O'Connor et al.   INTERNAL MEDICINE JOURNAL

P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease

(2013) J.F. Brandse et al.   Journal of Crohns & Colitis

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis

(2013) Xiaoping Zhang et al.   Expert Review of Clinical Pharmacology

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration

(2012) Wolfgang F. Richter et al.   AAPS Journal

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

(2012) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis

(2012) Hermine I. Brunner et al.   ARTHRITIS AND RHEUMATISM

A Guide to Rational Dosing of Monoclonal Antibodies

(2012) Shuang Bai et al.   CLINICAL PHARMACOKINETICS

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

(2012) Tomoyuki Imagawa et al.   CLINICAL RHEUMATOLOGY

Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children

(2012) Jeffrey S. Hyams et al.   GASTROENTEROLOGY

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rational development and utilization of antibody-based therapeutic proteins in pediatrics

(2012) Zhenhua Xu et al.   PHARMACOLOGY & THERAPEUTICS

Rituximab for Children with Immune Thrombocytopenia: A Systematic Review

(2012) Yi Liang et al.   PLoS One

Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register

(2012) J. Anink et al.   RHEUMATOLOGY

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

(2011) J. B. Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

(2011) Nicolino Ruperto et al.   ARTHRITIS AND RHEUMATISM

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

(2011) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension

(2011) Jeffrey Hyams et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients

(2011) T. Nagai et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

(2011) Suman Malempati et al.   JOURNAL OF CLINICAL ONCOLOGY

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

A Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal Sepsis

(2011) L. E. Weisman et al.   PEDIATRICS

Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

(2011) Tarundeep Kakkar et al.   PHARMACEUTICAL RESEARCH

Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

(2010) M. H. Otten et al.   ANNALS OF THE RHEUMATIC DISEASES

Les biothérapies en pédiatrie

(2010) A. Belot et al.   ARCHIVES DE PEDIATRIE

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

(2010) Pilar Fernández et al.   BMC Pediatrics

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome

(2010) Michael R. Pranzatelli et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

891 Population Pharmacokinetics Analysis of Motavizumab in Children at Risk for Respiratory Syncytial Virus Infection

(2010) L Zhao et al.   PEDIATRIC RESEARCH

1380 Predicted and Measured Pagibaximab Serum Levels in High-Risk Neonates

(2010) J F Kokai-Kun et al.   PEDIATRIC RESEARCH

Pediatric Dosing and Body Size in Biotherapeutics

(2010) Rong Shi et al.   Pharmaceutics

Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

(2009) Melanie S. Joy et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

(2009) L. E. Weisman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

(2009) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans

(2009) Brian J. Anderson et al.   Drug Metabolism and Pharmacokinetics

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

(2009) Tanya M. Trippett et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis

(2009) Ben-Fillippo Krippendorff et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

(2009) Anne L. Angiolillo et al.   PEDIATRIC BLOOD & CANCER

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

(2009) Katia Abarca et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

(2009) Koichi Kamei et al.   PEDIATRIC NEPHROLOGY

Rituximab in refractory nephrotic syndrome

(2009) Agnieszka Prytuła et al.   PEDIATRIC NEPHROLOGY

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Immunoglobulin Replacement Therapy in Children

(2008) Maria Garcia-Lloret et al.   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

(2008) Julia L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease

(2008) Jane C. Burns et al.   JOURNAL OF PEDIATRICS

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Palivizumab for Prevention of Hospitalization as a Result of Respiratory Syncytial Virus in Infants With Cystic Fibrosis

(2008) Michael E. Speer et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Human renal function maturation: a quantitative description using weight and postmenstrual age

(2008) Malin M. Rhodin et al.   PEDIATRIC NEPHROLOGY

Pharmacokinetics and Immunodynamics of Basiliximab in Pediatric Renal Transplant Recipients on Mycophenolate Mofetil Comedication

(2008) Britta Höcker et al.   TRANSPLANTATION

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology

The problems in scaling adult drug doses to children

(2007) T N Johnson   ARCHIVES OF DISEASE IN CHILDHOOD

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

(2007) Mark D. Pescovitz et al.   PEDIATRIC TRANSPLANTATION